FAQ: Immunotherapy in SCLC
Immunotherapy in SCLC: FAQ on Current Best Practice and Emerging Therapeutic Strategies

Released: August 27, 2020

Expiration: August 26, 2021

Anna F. Farago
Anna F. Farago, MD, PhD
Taofeek K. Owonikoko
Taofeek K. Owonikoko, MD, PhD

Activity

Progress
1
Course Completed

In this episode, Anna F. Farago, MD, PhD, and Taofeek K. Owonikoko, MD, PhD, answer questions focused on the topic of current and evolving use of immunotherapy in patients with advanced small-cell lung cancer with topics including:

  • Selecting between atezolizumab and durvalumab in the frontline setting
  • Integration of lurbinectedin, a novel anticancer drug that was recently approved for the treatment of relapsed SCLC after platinum-based chemotherapy, into patient care
  • Which patients should receive salvage therapy with an immune checkpoint inhibitor in the third-line setting
  • Management of brain metastases in patients with advanced SCLC

Content based on an online CME program supported by educational grants from Genentech, a member of the Roche Group, and Merck Sharp & Dohme Corp.

Link to full program, including associated downloadable slidesets: http://clinicaloptions.com/oncology/programs/io-sclc